Evidence map›Paper›PMID 41596463›Full record

Observational studyInternational journal of molecular sciences2026

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study.

Senthilkumar Sankararaman, Ruitao Liu, Xinyu Sun, Mauricio Retuerto, Terri Schindler, Erica Roesch, Thomas J Sferra, Mitch Drumm, Mahmoud Ghannoum, Liangliang Zhang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Senthilkumar SankararamanDivision of Pediatric Gastroenterology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.ORCID 0000-0003-3094-9703
Ruitao LiuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0009-0005-7778-0193
Xinyu SunDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0009-0002-2268-9518
Mauricio RetuertoCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Terri SchindlerDivision of Pediatric Pulmonology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
Erica RoeschDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Thomas J SferraDivision of Pediatric Gastroenterology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.ORCID 0000-0001-6893-9880
Mitch DrummDepartment of Genetics and Genomic Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0000-0003-4739-5153
Mahmoud GhannoumCenter for Medical Mycology, Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Liangliang ZhangDepartment of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

Funding

The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli · 2015 to 2026
$15.6M
NIDDK NIH HHS P30 DK097948Rainbow Babies & Children's Hospital Pilot Faculty Award - P0598
6 · The paper itself

Abstract

Prior studies in people with cystic fibrosis (CF) demonstrated a positive impact of ivacaftor on the stool microbiome. However, studies evaluating the impact of elexacaftor-tezacaftor-ivacaftor (ETI) on gut dysbiosis are limited. In this prospective, observational study, we evaluated the differences in stool microbiome in children (aged 2-17 years) with CF who were treated with ETI for at least two months and compared with children with CF who did not receive ETI. We also included healthy siblings as controls. There were no significant differences in the demographics between the groups. There were no significant differences in alpha diversity between the groups for both bacteriome and mycobiome. Alpha diversity showed a negative trend with the duration of ETI therapy for both bacteriome and mycobiome.

Indexed as

Chloride Channel AgonistsCystic FibrosisFecesGastrointestinal MicrobiomeAdolescentAminophenolsBenzodioxolesChildChild, PreschoolDrug CombinationsFemaleHumansIndolesMalePilot ProjectsProspective StudiesAminophenolsBenzodioxolesChloride Channel AgonistsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyridinesQuinolinesQuinolonestezacaftor, ivacaftor drug combinationcystic fibrosis (CF)dysbiosisgut microbiomemicrobiota

Identifiers

PMID41596463
PMCPMC12841031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.